Evidence map›Paper›PMID 42540187›Full record

ArticleACS omega2026

Development and Preclinical Evaluation of a Novel EpCAM-Targeted

Sato Oshige, Takumi Iwasawa, Yuki Naito, Hidekazu Kawashima, Takashi Kozaka, Marina Omokawa, Hiroyuki Fujimoto, Takiko Daikoku, Yusuke Yagi, Hiroyuki Yasui and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sato OshigeGraduate School of Medical Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
Takumi IwasawaInstitute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.
Yuki NaitoLaboratory of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Science, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Hidekazu KawashimaRadioisotope Research Center, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Takashi KozakaDivision of Probe Chemistry for Disease Analysis, Research Center for Experimental Modelling of Human Disease, Kanazawa University, Ishikawa 920-8640, Japan.
Marina OmokawaAdvanced Research Field, Okayama University, Okayama 700-8558, Japan.
Hiroyuki FujimotoAgency for Health, Safety and Environment, Kyoto University, Kyoto 606-8501, Japan.
Takiko DaikokuDivision of Animal Disease Model, Research Center for Experimental Modelling of Human Disease, Kanazawa University, Ishikawa 920-8640, Japan.
Yusuke YagiDepartment of Radiological Technology, Faculty of Medicinal Science, Kyoto University of Medical Science, Kyoto 622-0022, Japan.ORCID https://orcid.org/0000-0003-0937-3746
Hiroyuki YasuiLaboratory of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Science, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Kazunori KatoInstitute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.
Hiroyuki KimuraAgency for Health, Safety and Environment, Kyoto University, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0002-4291-3524

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial cell adhesion molecule (EpCAM) is overexpressed in various epithelial malignancies and represents an attractive target for molecular imaging and radionuclide therapy. This study aimed to develop and evaluate a novel EpCAM-targeted monoclonal antibody for single-photon emission computed tomography (SPECT) imaging. To this end, Ep4-1, a high-affinity anti-EpCAM monoclonal antibody, was conjugated to the bifunctional chelator

Identifiers

PMID42540187
PMCPMC13425302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.